Literature DB >> 15619548

The effect of fluoxetine in a model of chemically induced seizures--behavioral and immunocytochemical study.

Małgorzata Zienowicz1, Aleksandra Wisłowska, Małgorzata Lehner, Ewa Taracha, Anna Skórzewska, Piotr Maciejak, Adam Płaźnik.   

Abstract

The aim of this study was to examine the effects of acute fluoxetine treatment on pentylenetetrazol-induced convulsions in order to shape a model of seizures associated with treatment with antidepressants in rats. Moreover, the putative role of the hippocampal formation in this respect was investigated with the help of c-fos immuncytochemistry to mark local neuronal activity. It was found that fluoxetine (10.0 mg/kg, i.p.) enhanced the proconvulsive effect of pentylenetetrazol (50.0 mg/kg, i.p.), and simultaneously inhibited pentylenetetrazol-stimulated c-Fos expression in some areas of the hippocampus. Fluoxetine pretreatment did not alter pentylenetetrazol brain concentration indicating that this phenomenon was not related to the pharmacokinetic interaction. It is suggested that inhibition by fluoxetine of some neuronal populations contributing to the local feedback mechanism controlling excessive epileptiform discharges within the hippocampus might lead to an increase in epileptic activity. The reported in the present paper fluoxetine versus pentylenetetrazol interaction may, therefore, serve as a model of seizures associated with treatment with antidepressants.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15619548     DOI: 10.1016/j.neulet.2004.10.009

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  5 in total

1.  Elevated serotonergic signaling amplifies synaptic noise and facilitates the emergence of epileptiform network oscillations.

Authors:  Pavel A Puzerey; Michael J Decker; Roberto F Galán
Journal:  J Neurophysiol       Date:  2014-08-13       Impact factor: 2.714

Review 2.  Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder?

Authors:  L Cardamone; M R Salzberg; T J O'Brien; N C Jones
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

Review 3.  Therapeutic potential of fluoxetine in neurological disorders.

Authors:  Jop P Mostert; Marcus W Koch; Marco Heerings; Dorothea J Heersema; Jacques De Keyser
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

4.  Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome.

Authors:  Markus Heinen; Moritz M Hettich; Devon P Ryan; Susanne Schnell; Katharina Paesler; Dan Ehninger
Journal:  Neural Plast       Date:  2012-07-16       Impact factor: 3.599

5.  Decreased seizure threshold in an eclampsia-like model induced in pregnant rats with lipopolysaccharide and pentylenetetrazol treatments.

Authors:  Qian Huang; Lei Liu; Bihui Hu; Xiaodan Di; Shaun Patrick Brennecke; Huishu Liu
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.